Humacyte, Inc.
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsHumacyte is a commercial-stage biotechnology company that received FDA approval in December 2024 for Symvess, its bioengineered human tissue vessel for extremity arterial injury, and began U.S. commercial launch in the first quarter of 2025.
What they do
Humacyte develops and manufactures off-the-shelf, universally implantable, bioengineered human tissues at commercial scale, initially acellular tissue engineered vessels (ATEVs). Its lead product, Symvess, is approved for adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss and autologous vein graft is not feasible. The company is also running a Phase 3 trial of its 6 millimeter ATEV in arteriovenous access for hemodialysis and previously completed Phase 2 trials in peripheral artery disease. Longer-term programs include ATEV use in coronary artery bypass grafting, pediatric heart surgery, and delivery of cellular therapies such as pancreatic islet cells for Type 1 diabetes.
Revenue drivers
- Symvess (ATEV) U.S. commercial sales — The only approved product, launched in Q1 2025 for extremity arterial injury; quarterly revenue has been under $1 million per quarter to date, with Q2 2026 sales of $0.4 million.
- Dialysis access (AV access) development program — Not yet revenue-generating; a Phase 3 program in 6 millimeter ATEV for hemodialysis access, with a supplemental BLA planned for the second half of 2026, is the nearest-term pipeline opportunity.
- Peripheral artery disease (PAD) program — Not yet revenue-generating; Phase 2 trials were previously completed and the ATEV received RMAT designation for advanced PAD in June 2024.
- Early-stage programs (CABG, pediatric heart surgery, BVP) — No revenue; CABG development is advancing with an accepted IND and a planned Phase 2a study in Q3 2026, while BioVascular Pancreas and other applications remain longer-term.
Recent performance
Annual revenue was $2.0 million in 2025 versus none in 2024, and recent quarterly revenue has declined sequentially from $753,000 in Q3 2025 to $406,000 in Q2 2026. Net loss was $40.8 million in 2025, improved from $148.7 million in 2024. Operating cash use was $105.0 million in 2025, up from $98.1 million in 2024. At June 30, 2026, Humacyte reported $79.9 million in cash and equivalents, $106.8 million in total liabilities, $36.3 million in long-term debt, and $31.3 million in shareholder equity.
Strategy
Management is prioritizing the U.S. commercial ramp of Symvess by rebuilding the commercial team with vascular surgery relationships and refining pricing and value-analysis-committee processes. It plans to file a supplemental BLA for dialysis access in the second half of 2026, based on V012 Phase 3 interim results in female dialysis patients and prior V007 Phase 3 results. The FDA accepted an IND for the CTEV in CABG, and a Phase 2a study is expected to start in Q3 2026. Longer term, Humacyte continues to pursue additional ATEV indications including PAD, CABG, pediatric heart surgery, and cellular therapy delivery such as the BioVascular Pancreas.
Risks
- Continued losses and cash consumption — Humacyte reported a $40.8 million net loss in 2025 and used $105.0 million of operating cash, with only $79.9 million of cash and equivalents at June 30, 2026.
- Listing-rule compliance — The company disclosed delisting notices or listing-rule failures in 8-K filings on May 8, 2026 and July 31, 2026.
- Early commercial ramp — Symvess quarterly sales have not exceeded $0.8 million in any reported quarter and declined sequentially through Q2 2026, despite the U.S. launch beginning in Q1 2025.
- Regulatory and pipeline dependence — The dialysis access supplemental BLA has not yet been filed, and the CABG Phase 2a study has not yet started, so future growth depends on clinical and regulatory outcomes beyond the single approved indication.
Outlook
Management expects to file a supplemental BLA for the ATEV in dialysis access during the second half of 2026, citing V012 Phase 3 interim results in female patients showing the ATEV outperformed AV fistula and reduced catheter use. It also plans to start a Phase 2a study of the CTEV in CABG in Q3 2026 after FDA acceptance of the IND. Management says it is seeing early signs of hospital adoption and strengthening utilization from its rebuilt commercial effort as it enters the second half of 2026.